Dr. Daniel J. Drucker

Areas of Focus

Diabetes

Dr. Daniel Drucker's lab is internationally renowned not only for his research, but as an environment where the clinical relevance of scientific breakthroughs is pursued. His lab has carried out basic science supporting the development of two new classes of therapies for the treatment of type 2 diabetes and a new therapy for patients with short bowel syndrome requiring parenteral nutrition. His research also shows tremendous promise for the treatment of obesity.

Dr. Drucker studies a family of hormones produced in the pancreas, gastrointestinal tract and brain. Controlling blood glucose and insulin secretion, these hormones also regulate our appetite, the absorption of nutrients from the food we eat, and the conversion of those nutrients to energy. In his lab, Dr. Drucker studies the action of hormones that regulate multiple aspects of metabolism. Since enhanced gut hormone action may be beneficial in diabetes, obesity and inflammatory bowel disorders, these hormone analogues have potential to lead to new treatments for diseases that afflict millions of people worldwide.

Contact [email protected]

416-586-4800 ext. 2308

Location

Lunenfeld-Tanenbaum Research Institute
Mount Sinai Hospital
600 University Ave.
Toronto, Ontario
M5G 1X5

Quick links

Glucagon
Web of Science Researcher ID A-4092-2010
Web of Science publications

At a glance

Dr. Daniel Drucker is a clinician-scientist who develops treatments for diabetes, obesity, and intestinal disorders.

He studies peptide hormones produced in the pancreas, gastrointestinal tract and brain.

His lab has carried out basic research leading to two new treatments for type 2 diabetes and one new therapy for short bowel syndrome.

He holds the Canada Research Chair in Regulatory Peptides and the Banting and Best Diabetes Centre-Novo Nordisk chair in Incretin biology.

Major research activities

A pioneer in diabetes treatment, Dr. Drucker's work has provided important insights leading to the development of new drugs for the treatment of type 2 diabetes. Currently, his laboratory at the Lunenfeld-Tanenbaum focuses on understanding the molecular biology and physiology of glucagon-like peptides.

Recognition for Dr. Drucker’s research includes

The 2009 Clinical Investigator Award from The Endocrine Society, Washington, USA

Recipient of the 2011 Oon International Award for Preventive Medicine, Cambridge University School of Medicine, UK

2014 Banting Medal for Scientific Achievement, American Diabetes Association, USA

2014 Manpei Suzuki International Prize for Diabetes Research, Manpei Suzuki Foundation, Japan

2015 Elected Fellow of the Royal Society of London, UK

2015 Appointed Officer of the Order of Canada